Telix Pharmaceuticals Limited
TLPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.20 | -5.90 | -1.20 | -0.39 |
| FCF Yield | 0.11% | 0.41% | -3.62% | -2.75% |
| EV / EBITDA | 80.28 | 135.72 | -22.02 | -31.19 |
| Quality | ||||
| ROIC | 6.06% | 36.13% | -55.22% | -91.15% |
| Gross Margin | 65.08% | 62.56% | 18.32% | -391.85% |
| Cash Conversion Ratio | – | 4.58 | 0.61 | 0.74 |
| Growth | ||||
| Revenue 3-Year CAGR | 69.76% | 304.45% | 213.16% | 29.66% |
| Free Cash Flow Growth | -31.27% | 116.82% | -28.29% | -3,803.72% |
| Safety | ||||
| Net Debt / EBITDA | -1.31 | -4.61 | 1.14 | 0.28 |
| Interest Coverage | 3.83 | 3.83 | -226.43 | -429.88 |
| Efficiency | ||||
| Inventory Turnover | 7.17 | 10.87 | 22.67 | 10.82 |
| Cash Conversion Cycle | 33.32 | 27.65 | 40.18 | 919.28 |